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Translocation (12;22) (pl3;qll) in myeloproliferative disorders results in 
fusion of the ETS-like TEL gene on 12pl3 to the MN1 gene on 22qll
Aijtin Buijs, Scii ah Sheri1, Sjozef van Baal1, Saskia van Bezouw1, Dorien van der Plas3, Ad Geurts
van Kessel1, Petei Riegman~, Ronald Lekanne Deprez2, Ellen ZwarthofP, Anne Hagemeijer3 and 
Gerard Grosveld1
Tennessee 38101-0318, USA; Departments 
3000 DR Rotterdam, The Netherlands; 
Nijmegen, The Netherlands
In myeloid and lymphoid leukemias recurrent chromoso­
mal aberrations can be detected in chromosome region 
12p!3. We characterized the genes involved in t(12;22) 
(p l3 ;q ll)  in two patients with myeloid leukemia and one 
with myelodysplastic syndrome (MDS). MN1, a gene on 
chromosome 22qU was shown to be fused to TEL, a 
member of the family of ETS transcription factors on 
chromosome 12pl3. The translocation results in tran­
scription of the reciprocal fusion mRNAs, MN1-TEL 
and TEL-MN1, of which MN1-TEL is likely to encode 
an aberrant transcription factor containing the ETS 
DNA-binding domain of TEL. In addition to fusion of 
TEL to the PDGF/J receptor in t(5;12) in chronic 
myelomonocytic leukemia (CMML), our data suggest 
that the involvement of this protein in myeloid 
leukemogenesis could be dual; its isolated protein- 
protein dimerization and DNA-binding domains may be 
crucial for the oncogenic activation of functionally 
different fusion proteins.
Keywords: iranslocution; TEL: M N1 ; myeloid leuke­
mia; chromosome 12p
Introduction
The translocation ( 12;22)(pl3;ql 1) has been associated 
with myeloid malignancies of different FAB subtypes. 
Originally it was found as an alternative translocationW *
in chronic leukemia (CML) and it was 
proposed that the 2 2 q -  chromosome was an 
alternative Philadelphia chromosome (Engel et al., 
1977; van der Blij-Philipsen et alM 1977; Verma and 
sik, IW ) ,  However, later the same specific 
transloeation was also found in rare cases of acute 
myeloid leukemia (AML) M l, M7, M4 and MDS 
(Hagemeijer et atM 1981 ; Johansson et a i , 1990; Callen 
et aL  1991; Mitelman, 1991; Kashimura and 
Minamihisamatsu, Th e e h ro m o s o m a 1 regi o n 
12p 11-13 has been implicated in the genesis of 0 .5 - 
2% of different myeloid (Adriaansen, 1992) and 10% 
of childhood acute lymphoblastic leukemias (ALL) 
(Raimondi et al., 1986). In the case ol myeloid 
leukemias, this often involves balanced translocations 
with a collection of different partner chromosomes 
(Mitelman, 1991), which is also true for the specific 
sub-band I2pl3, involved in t(12;22). In ALL the
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region is often deleted, but also balanced translocations 
have been described (Raimondi et a l , 1986; Mitelman, 
1991; Krance et a l , 1992; van der Plas et a l , 1995), 
With respect to the cytogenetic data, different loci, 
present on 12pll, 12pl2 and 12pl3, may be involved 
in these malignancies (Mitelman, 1991).
Our interest in this specific but rare translocation in 
myeloid malignancies was raised by the 2 2 q l l  break­
point and its association with aspecific CML, which 
indicated a possible involvement of the BCR  gene. 
However, initial mapping experiments with BCR 
cDNA probes excluded this possibility and the use of 
rodent/human hybrid cell lines, containing the segre­
gated chromosomes of a patient with t(12;22) AML, 
suggested that the translocation breakpoint mapped 
telomeric from the BCR gene on chromosome 22 
(DvdP, unpublished results). We set out to molecularly 
identify t(12;22) with the idea that it represented a 
crucial tumorigenic step in the genesis of myeloid 
malignancies and that the same locus on 12pl3 may be 
involved in other chromosome translocations.
Using hybrid cell lines from a patient with t(12;22) 
AML-M4, we could map and clone the genomic 
chromosomal'breakpoint on 22qll. It was situated in 
the intron of MN1 , a candidate gene for meningioma, 
encoding a protein with features characteristic of 
transcription factors (Lekanne Deprez et al., 1995, 
this issue). This allowed us to clone chromosome 12 
sequences and to isolate fusion cDNAs, using a RT- 
PCR cloning procedure. The translocation results in 
the fusion of the MN1 gene to the recently identified 
TEL gene on 12pl3, a member of the ETS gene 
family of transcription factors (Golub et al., 1994). 
The amino-terminal part of the TEL protein, contain­
ing a putative protein-protein dimerization domain, 
was found to be fused to the tyrosine kinase domain 
of the PDGF/? receptor by the t(5; 12)(q34;p 13) in 
chronic myelomonocytic leukemia (CMML). In two 
out of three patients with different myeloid malig­
nancies, carrying t(12;22), both the TEL-MN1 and 
MN1-TEL fusion mRNAs are expressed. In  hybrid 
cell lines of the third patient, only expression of MN1- 
TEL mRNA could be found. This transcript will 
encode a fusion protein, containing an ETS DNA- 
binding domain, that may act as an altered 
transcription factor, similar to EWS-FLI1 in Ewing's 
sarcoma (Bailly et a l 1994). Our data suggest that 
the involvement of TEL in human myeloid malig­
nancies is dual. Distinct domains of the protein seem 
to be essential constituents of functionally different 
fusion proteins.
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Results
Localization o f chromosomal breakpoint on 22qll
To localize the 22qll breakpoint of t(12;22), probes of 
known localization in the 22qll-ql3 region were 
hybridized to DNA of somatic cell hybrids, containing 
the segregated translocation chromosomes of a t(12;2 2 )
AML patient. To this end, bone marrow cells of a 
patient (pi) with t(12 ;2 2 ) AML were fused to the 
hamster cell line A3 using standard procedures (Geurts 
van Kessel et a i , 1981). After selection, individual 
clones were picked and characterized cytogenetically, 
using Reverse banding techniques. The chromosomal 
content of the relevant hybrid cell lines is shown in 
Table 1. DNA of human thymus, hamster cell line A3
Table 1 Hybrid cell lines containing segregated t(12;22) chromosomes scored for chromosome 22q-specific markers
centromere / Markers telomere
Chromosomes
1.8 kb 
£ cöRI76A4
2.2
MN1
17.13'
MN1
/
Cell Line* 12 12p+ 22 22q 5'BCR D22S1 Cosmid cDNA cDNA D22S193 D22S56 LIF D22S15 c-sis
A3 JA 19A + 4* + + + + 4- + + + +
A3 JA 19C + — — — — — — — — - — —
A3 JA 13B — — — — — + + — — i |»i «p|m + 4-
A3 JA 12 A + - — + + + — — - — —
A3JA 1C + +
A3JA 2B — + —
A3 JA 12C — + +
A3JA 20A + + — —
A3 JA 14B + - + +
Chromosome; + chromosome seen in at least 5/10 metaphases. Marker: + positive hybridization signal; -  no hybridization signal. *: the hybrid 
cell lines have additional human chromosomes not listed in this table
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Figure 1 (a) Schematic representation of human chromosome 22. Indicated are several loci with respect to t(12;22)(pl3;qll) (b) 
Restriction map of MN1 on chromosome 22. Indicated below the map are probes E l.8, cDNA 2.2, EH 1.4, pUK4, cDNA 17.1 3' 
and D22S193 and cosmids clones 76A4 and 50B11. Localization of exons are indicated with black boxes, (c) Restriction map of 
TEL on chromosome 12. The t(12;22) breakpoints of patients 1, 2 and 3 are shown (pi, p2 and p3). Below the map, the phage 
contig is shown of which clones MR41 to MR40 were isolated by chromosome walking starting with chimeric phages containing the 
(12;22) breakpoint of p2. MR43 to MR47 were isolated by hybridization with TEL cDNA clone hpc7A to a genomic phage library. 
The cDNA hpc7A is depicted underneath the phage contig. The positions of the type I and II in t(12;22) and the t(5;12) fusions are 
indicated by arrows. Dashed lines indicate genomic fragments (black boxes) that cross-hybridize to hpc7A sub fragments. These 
genomic fragments were delimited by various restriction enzyme sites, not shown in this map. HLH = Helix-Loop-Helix domain; 
DBD = ETS DNA-binding domain; E«£coR I, S =  SacI, B =  X ^ X h o l
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Figure 2 Localization of breakpoints on chromosome 22 in p i  and p2 (a) A Southern blot containing DNA of hamster cell line 
A3, hybrid cell lines with the segregated translocation chromosomes derived from bone marrow of p i,  bone marrow of p2 (2) and 
human thymus D N A  (N) was digested with EcoRi, BamHI , Bg [II or Hindili. Southern blots were hybridized with a 1.4kb EcoRI ~ 
I f  indill fragment, located at the 5' side of the 60 .kb intron in M N L  Sizes of normal fragments are indicated (in kb) and arrowheads 
indicate aberrant fragments (b) D N A  of bone marrow from p2(2) and human thymus (N), digested with EcoKl, BamHI, %/If, 
HindllI or Pstl  was hybridized with 4.4 kb EcoKl fragment p'UK4. Sizes o f  molecular weight markers are shown (in kb).
Arrowheads indicate aberrant fragments 
shown in the middle o f  the figure
and p;2 is
and hamster/human hybrid cell lines A3JA 19A (#22), 
A3JA 19C (#12), A3JA 13B (#12p+) and A3JA 12A 
(#12,22q_) was digested with EcoKl and BamHI. 
Southern blots were hybridized to 5'BCR, D22S1, 
D22S56, LIF, D22S15 and c-sis (for relative position of 
probes, see Figure la), respectively. The former two
19A and A3JA 12A, whereas the latter four hybridized
with DNA of hybrid cell lines A3JA 19A and A3JA 
13B (Table 1), indicating that the breakpoint was 
located between D22S1 and D22S56. Subsequent 
hybridization with probes from this area, D22S193 
and a single copy 1.8 kb EcoRi fragment, mapping 
between D22S1 and D22S56, revealed that D22S193 
was not translocated in pi, while the 1.8 kb EcoRi 
fragment was. These two probes are derived from a
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1 5 1 4
cosmicl contig spanning the translocation breakpoint 
on chromosome 22q 11 of a meningioma *1 C' O yF*\/,‘>*l f.
balanced translocation t(4;22)(pl6;qll), in a patient 
with sporadic meningiomas (Lekanne Deprez et a l , 
1991) (Lekanne Deprez et a l 1995, this issue). The 
physical distance between the probes is 100 kb (Figure 
lb), spanning a region containing a gene called MN1, 
consisting of two large exons separated by an intron of 
60 kb, oriented with its 3' end toward the centromere 
of chromosome 22 (Figure lb). To analyse whether 
MN1 was directly involved in t(12;22), we hybridized
cDNA probes 2.2 (1.5 kb) and 17.1 3' (1.4 kb), derived 
from the 5' and 3' exon, respectively (see Figure lb). As 
shown in Table 1,’cDNA 17.1 3' hybridizes with DNA 
derived from cell line A3JA 12A (# 12,22q ), but not with 
DNA derived from A3JA 1C (# i2,12p+), while cDNA
(# 12p +).
MN1  contains the 22ql l  
breakpoint of the t(12;22) in pi. To map the position of
(see Figure lb) were hybridized to Southern blots 
containing DNA of the hybrid of this patient digested 
with £cuRL BamHl, Bglll and Hindlll. One of these, 
probe EH 1.4 (Figures l b and 2 a and b), detects a normal 
7.7 kb EcoKl fragment in DNA of hybrid cell line A3JA 
19A (#22), A3JA 2B (#22,12p+) from p i,  in bone 
marrow DNA of p2 and normal human thymus DNA 
(Figure 3b), but an aberrant fragment of 5.7 kb in cell 
lines A3JA 1C (# I2 , 12p)  and A3JA 2B. To exclude an 
¿fcoRI polymorphism, aberrant fragments were also 
detected in BamHl and Bglll digested DNA of these cell 
lines (20 and 12 kb, respectively).
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Figure 3 Fluorescent in situ hybridization and localization of the breakpoint on chromosome 12pl3 in p i.  (a) Chimeric T E L -M N l  
12-22 phage clone MR2 from p2 was hybridized to metaphase chromosomes of normal hum an blood. Right, panel shows position of 
chromosomes 12 and 22 with DA PI staining. Hybridization of M R2 to the short arm of chromosome 12 (strong signal) and the 
long arm of chromosome 22 (weak signal) is indicated with an arrow. Localization of chimeric phage clones M R  20 and M R 2 on 
the physical map of the 12p 13 region is shown at the bottom of (b). Sequences derived of chromosome 12 are indicated with bold 
lines whereas sequences derived from chromosome 22 are indicated with thin lines (b) DNA derived from hamster cell line A3, 
hybrid cell lines containing the relevant translocation chromosomes of pi (I), bone marrow of p2 (2) and normal thymus (N) was 
digested with EcoRI, B am H l ,  tig ill or Hindlll. The Southern blot was hybridized with a single-copy 0.3 kb Rsal fragment (RR0.3). 
Sizes of normal fragments are indicated (in kb), aberrant fragments are indicated by an arrow. The physical map of the chromosome 
12p 13 region is shown at the bottom of the figure and the position of phage clones M R36 and M R2 and MR20 is indicated. Probes 
used to localize the 12p ’’ breakpoint of pi (1) are shown underneath
A similar approach was followed to find the 
breakpoint in the MN1  gene in the bone marrow 
DNA of p2. The 4.4 kb EcoRl intronic fragment 
(pUK4; see Figure lb  and 2b) detects aberrant 
fragments of 20  kb and 2 .2  kb in addition to the 
normal EcoRl fragment of 4.4 kb (Figure 2b). Aberrant 
fragments were also detected in BamHl, Bglll, Hindlll 
and Pstl digested DNA of p2. These results indicate 
that the breakpoints on chromosome 22  in p i and p2 
are located in close proximity to one another at the 5' 
side of the 60 kb intron of M N 1 .
Localization o f  the breakpoints on chromosome 12p
To identify the breakpoints of these patients on 
chromosome 12pl3, a genomic AEMBL3 library (106 
pfu) was constructed of bone marrow DNA from p2 
(MERO 12/22 library). From the recombinant phages 
hybridizing with probe pUK4, eight out of 13 showed 
restriction patterns that in part diverged from the wild- 
type MN1  restriction map and contained EcoRl 
fragments of aberrant size. Of these phages, MR20 
and MR2 appeared to contain the chromosome 12pl3 
and 22qll specific breakpoints, respectively (Figure 
3b). To verify whether MR2 indeed contained 
sequences derived from chromosome 12, the phage 
was used as probe in a fluorescent in situ hybridization 
experiment (FISH) on metaphase chromosomes from 
human peripheral blood. As shown in Figure 3a, MR2 
clearly hybridized to chromosome 12 band p l 3 , 
confirming its alleged chromosomal position. Since 
this phage clone also contains 0.7 kb of chromosome 
2 2  sequences, a faint signal on chromosome 22  is 
visible. Similar data were obtained with phage MR20 
(not shown). Mapping of phage clones MR2, MR20 
and wild-type phages of a contig derived from this 
region (Figure lc), revealed that the breakpoint of p2 is 
located in a 1.0 kb E coR l-H ind lll  fragment (see 
Figure lc). The breakpoint on chromosome 12 in pi 
could be detected by Southern blot analysis of the 
hybrid cell lines using chromosome 12-specific probes 
(HH3.0, HH3.5, EE1.5 and EE1.0, Figure 3b). Of 
these, HH3.5, EE1.5 and EE1.0 remain on the 12p+ 
chromosome, while HH3.0 is translocated to the 22q~ 
chromosome (not shown). A single copy 0.3 kb Rsal 
fragment (RR0.3, Figure 3b) from this region, detected 
aberrant fragments containing the chromosome 12pl3 
breakpoint in EcoRl, BamHl, Bglll and Hindlll 
digested DNA of hybrid cell lines A3JA 1C and 
A3JA 2B (Figure 3b). Exact mapping of the breakpoint 
showed that it is situated 13.5 kb telomeric from the 
12pl3 breakpoint in p2 .
RACE-PCR cloning
Due to restricted amounts of patient material, we 
analysed the presence of aberrant mRNAs by RACE- 
PCR (rapid amplification of cDNA ends) (Frohman et 
a l , 1988; Belyavsky et a l , 1989). To analyse expression 
of 5' chromosome 12/3' MN1 chimeric mRNA, 1 /¿g of 
poly(A)+ RNA of p2 was primed with a 3' MN1- 
specific antisense primer for first strand cDNA 
synthesis (Figure 4a, primer 1). This product was then 
amplified using a 5' anchor primer and a nested 3' 
MN1 primer (Figure 4a, primer 2). A PCR fragment of 
440 bp (not shown) was subcloned and sequenced. The
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fragment contains 282 bp of new 5' sequences spliced 
to the 3' exon of MN1. In the reading frame of the 
MN1 moiety of the clone, the new sequence contains 
an open reading frame with a possible AUG start 
codon 163 bp 5' of the MN1 sequence. Comparison of 
the predicted protein sequence with the recently 
published sequence of TEL (Golub et a l , 1994), 
showed that they were identical. TEL is a member of 
the ETS family of transcription factors and contains, in 
addition to the carboxyl-terminal ETS DNA-binding 
domain, a putative helix-loop-helix (HLH) protein 
dimerization domain, located at the amino-terminal 
side of the protein. In t(5;12) in CMML the HLH 
domain of TEL is fused to the kinase domain of 
PDGFR/J. However, in our case, the breakpoint in the 
TEL gene occurs at a position 5' of the HLH coding 
sequence. Therefore the TEL-MN1 mRNA would 
encode a protein of 12 kDa containing the first 54 
amino acids of TEL fused to the last 59 amino acids of 
MN1, not including the HLH domain of TEL.
Expression of the complementary MN1-TEL fusion 
mRNA, was tested by RT-PCR analysis using 
antisense TEL primers (Figure 4a, primers 4 and 5). 
Poly(A)+ RNA of p2 (1 ¡xg) was used to perform a RT- 
PCR reaction with M N 1 sense primer 3 and TEL 
antisense primer 4 (see Figure 4a). Part of this reaction 
was used for a second round of PCR with the same 
MN1 primer 3 and a nested antisense TEL primer 5 
(see Figure 4a). After gel electrophoresis, a 550 bp 
product was visible (not shown), matching the size 
expected for the MN1-TEL fusion cDNA which was 
subsequently confirmed by sequence analysis. There­
fore, the respective mRNA is calculated to encode a 
fusion product of 177 kDa, containing the first 1259 
amino acids of MN1 fused to the last 397 amino acids 
of TEL, including the helix-loop-helix (HLH) protein 
dimerization domain (Figure 4a; type I).
Consistent expression of both fusion mRNAs was 
analysed in the other two t(12;22) patients, p i and p3. 
RT-PCR analysis was done on 5 ¡ig of total RNA of 
hybrid cell lines A3JA 2B (#22,12p+), A3JA 1C 
(#12,12p+), A3JA 20A (#12,12p+) and A3JA 12C 
(#22q- , 12p+) for pi and on bone marrow RNA for 
p3. Unfortunately, RNA from hybrid cell lines had to 
be used for p i, since leukemic cells were no longer 
available. In all hybrid cell lines containing the 12p+ 
chromosome, the same 550 bp MN1-TEL cDNA was 
amplified, while in cell lines A3JA 14B (# 12,22,2 2q~) 
and A3JA 12C (# 12p +,2 2q~) no TEL-MN1 cDNA 
could be amplified. RT-PCR amplification of p3 RNA 
from bone marrow cells produced both a TEL-MN1 
and a MN1-TEL-specific product, but the first 
appeared 165 bp longer and the second 165 bp shorter 
than the concomitant fusion cDNA products of p 1 and 
p2. Cloning and sequence analysis of these amplified 
fragments showed that the breakpoint in the TEL 
coding sequence occurs 165 bp farther 3', explaining 
the discrepancy in size of the amplified cDNA 
fragments. The breakpoint in the TEL coding 
sequence is located within the HLH region, indicating 
that neither of the predicted fusion proteins will 
contain the intact HLH domain of TELl We designate 
the fusion in pi and p2 as type I and p3 as type II 
(Figure 4a). Figure 4b shows the sequence around the 
breakpoint areas of both types of reciprocal fusion 
cDNAs, which in type I occurs at TEL codon 55 and
1515
in type II at codon 110. As a result the type II TEL- 
MN1 and MN1-TEL mRNAs would encode for 
19 kDa and 170 kDa fusion proteins, respectively.
cDNA cloning and partial genomic organization o f  the 
TEL gene
A human placenta cDNA library of a complexity of 
106 pfu was hybridized with the 5' TEL-specific 246 bp 
E co B l-X h o l  fragment of the TEL-MN1 fusion cDNA 
fragment of pi. Many hybridizing plaques were 
isolated of which we analysed one with an insert of 
1.7 kb (hpc7A) that contained the entire open reading 
frame of TEL as well as 5' and 3' UTRs of 106 bp and 
199 bp, respectively. This cDNA clone was hybridized 
to the genomic MERO 12/22 2EMBL3 library of p2 
and out of 100 hybridizing plaques 20  were isolated 
and analysed. A partial physical map of TEL  is shown 
in Figure lc. Restriction analysis of phage MR44 
revealed that it has overlap with MR40, which belongs 
to a phage contig of 100 kb that was isolated with the
Fusion between MN1 and TEL in myeloproliferative disorders
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12pl3 breakpoint of p2 as a starting point. Subfrag­
ments of hpc7A were hybridized to the entire phage 
contig to identify fragment containing exons. The 
541 bp X h o l-S a c l  TEL cDNA fragment hybridizes 
with the 2.2 kb X h o l-E co R l  fragment of MR43, the 
12.5 kb S a il-E c o R l  fragment of MR40, the 8 kb 
ifcoRI fragment of MR44 and the 4.3 kb EcoRl 
fragment of MR46. Sequencing of the 2.2 kb X h o l-  
ifcoRI fragment of MR43 showed that the exon/intron 
border coincides with the type I fusion point in the 
cDNA. The breakpoints in the TEL fusion cDNAs of 
our p i and p3 and the published CM M L patients 
(Golub et ah, 1994) (i.e. 5', within, and 3' of the TEL 
HLH sequence, respectively) mark the borders of 
different TEL  exons. Since the type II and t(5;12) 
CMML breakpoint map at least one exon apart and 
primer 4 (located between those breakpoints) hybri­
dizes with the 8 kb EcoRl fragment in phage MR44 
(Figure lc)} we deduce that the breakpoint of p3 is 
located within an intron between these exons within 
this fragment. From the hybridization pattern of 5' and
Pr3 Pr2 Pr1
Pro Pr5 Pr4
bdtiiltMT'fTl
Type I
cDNA MN1
cDNATEL
d i
Type II
fusion cDNAs MN1-TEL 
and TEL-MN1
b
Type PCR products
MN1 TEL
5’ CAG AAC CCC AAC AGC AAA GAA GGC TTG CAG CCA ATT TAC TGG AGC 3’
Q N N K E G55 Q p W
Pr3 - Pr5 550 bp
TEL T ♦ MN1
5’ ATC CGC CTG CCT GCG CAC CTG CCC CAC GAC CTC CCT GCA AAC AAG 3’
I R L P A H L P H D L P A N K
1260
Pr6 - Pr2 310 bp
Type II
MN1 «-------[------ ► TEL
5' CAG AAC CCC AAC AGC AAA GAA GGT GAT GTG CTC TAT GAA CTC CTT 3’ Pr3 » Pr5 385 bp
q n p n s k e g d v l y e l l
110
TEL «-------1------ ► MN1
5' CGC TAT CGA TCT CCT CAT TCA GCC CAC GAC CTC CCT GCA AAC AAG 3’ Pr6 - Pr2 475 bp
R Y R S P H S A H D L P A N K
1260
Figure 4 Schematic representation of cDNAs and breakpoint regions in t(12;22) (a) cDNAs of normal MN1 and TEL and the 
reciprocal type I and II fusion products. ORFs of MN1 and TEL are shown in black and gray, respectively. Horizontally striped 
boxes indicate the HLH domain of TEL, whereas vertically striped boxes indicate the ETS-domain. Primers used in RT-PCR 
reactions are indicated above the MN1 and TEL cDNAs. (b) Sequences of reciprocal fusion cDNAs around the type I and II 
breakpoints. Amino acid sequences deduced from the nucleotide sequence are shown in one-letter code below. Numbers indicate in 
which codon of TEL and MN1 the fusion occurs for both types of translocations. The number on the right side indicates the length 
of the PCR fusion cDNAs with the different primer combinations
3' genomic TEL  fragments to the panel of hybrid cell
lines of p i we conclude that the gene is located in a 5'
telomeric 3' centromeric orientation on 12pl3. This
orientation is in agreement with the orientation of the
PDGFR/J (Morris et al, 1992) on chromosome 5q33
and MN1  on chromosome 22qll (Lekanne Deprez et
a l,  1995, this issue), predicting that fusion of these
genes with TEL  are the product of conventional 
balanced translocations.
Discussion
In this paper we show the existence of new leukemia 
specific fusion genes TEL-M N l  and MN1-TEL  as the 
result of the t(12 ;2 2 ) in different myeloid malignancies. 
The fact that in three out of three patients the same 
two genes are involved in the translocation provides 
compelling evidence for a direct role of the fusion 
products in the leukemic process. In contrast to most 
chromosome translocations both chimeric gene deriva­
tives are expressed in patient bone marrow cells. 
However, the observation is not unique as it was 
consistently found in acute promyelocytic leukemia 
(APL) (Alcalay et al., 1992), where both PML-RARa 
and RARa-PML RNAs are expressed. In the hybrid 
cell lines of p i ,  containing chromosome 22q~, no TEL- 
M N l transcript could be amplified. Since the transcript 
was present in bone marrow cells of the two other 
patients, we suspect that its absence is due to silencing 
in the hybrid cell lines. Although we find both fusion 
RNAs using RT-PCR, we do not know their relative 
levels of expression in patient cells. Due to lack of 
patient material, we were not able to perform Northern 
blot hybridizations and we did not attempt to 
quantitate the RT-PCR approach.
The translocation involves the recently described 
ETS-related gene, TEL , and a gene with a possible role 
in meningioma, M N L  Golub et al (1994) found TEL 
to be fused to the PDGFR/J gene in CMML, a specific 
subtype of myelodysplastic syndrome (MDS). TEL 
mRNA encodes a typical ETS-related transcription 
factor belonging to the subgroup that have the DNA- 
binding domain at the carboxyl-terminal end and a 
HLH protein-protein interaction domain at the amino- 
terminal side (Wasylyk et a l , 1993). In CMML, only 
the TEL-PDGFR/3 fusion transcript is expressed, while 
the complementary fusion gene, which would contain 
the DNA-binding domain, is silent. Because the 
breakpoint occurs just 3' of the HLH-domain, Golub 
et a l  (1994) suggested that, in addition to ectopic 
expression of the PDGF/? receptor by the TEL 
promoter, the putative dimerization motif may be 
important for ligand independent tyrosine kinase 
activation of the TEL-PDGFR/? fusion protein. In 
our fusion products, the breakpoint occurs just 5' or 
within the HLH region (depending on the type of 
fusion), suggesting that this dimerization domain is 
nonessential for the function of the fusion proteins in
t(1 2 ;2 2 ) leukemic cells.
The possible function of the MN1 protein is much
less clear. As shown by Lekanne Deprez et al (1995, 
this issue) the gene was cloned from a t(4;22) in an 
isolated case of meningioma and the encoded protein 
does not show significant homology to any known 
protein sequences. The only clue obtained so far is its
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alleged nuclear localization. This preliminary observa­
tion in combination with the glutamine/proline-rich 
amino-terminal sequence of the protein, a feature 
found in the activation domains of transcription 
factors (Gerber et a l , 1994), may indicate a role in 
transcription activation. However, whether MN1 
would function as a classic DNA-binding transcription 
factor or as transcription factor associating protein 
remains to be determined.
As yet there are no clues whether TEL-MNl, MN1- 
TEL or both are important for transformation of early 
myeloid precursors in t(12;22). Upon evaluation of 
their features we favor the latter product as a potential 
oncogene, since it has the structure of an altered 
transcription factor. It contains the carboxyl-terminal 
part of the TEL protein providing the ETS DNA- 
binding domain linked to almost the entire MN1 
protein, including the glutamine/proline-rich stretches. 
This structure is highly reminiscent of the EWS-FLI1 
and EWS-ERG1 fusion proteins in Ewing’s sarcoma, 
where the glutamine/proline-rich amino-terminal part 
of the EWS protein is linked to the ETS domains of 
FLI1 or ERG (Delattre et a l 1992; Sorensen et a l ,
1994). It was shown that substitution of normal amino- 
terminal FLI1 by EWS sequences creates a transcrip­
tion factor with much stronger transactivation 
potential (May et a l , 1993; Bailly et a l , 1994). 
Although it has not been analysed, it is reasonable to 
speculate that this is in part due to its glutamine/ 
proline-rich sequences of EWS, making it plausible that 
MN1-TEL could have similar characteristics. In 
addition, fusion of MN1 could enhance the DNA 
binding affinity of the TEL moiety of the protein, by 
interference with a possible intra-molecular interaction 
in TEL that was shown to regulate DNA binding in 
several other ETS family members (Lim et a l , 1992; 
Wasylyk et a l , 1993). Both possibilities are currently 
under investigation.
Regulation of transcription activity of several 
members of the ETS family, like Elkl and SAP in 
mouse (Janknecht et a l , 1993; Marais et a l , 1993; 
Hipskind et a l , 1994) and pointed and yan in D. 
melanogaster (Brunner et a l , 1994), is directed by 
phosphorylation by mitogen activated protein kinase 
(MAPK), that in turn is activated by several signal 
transduction pathways, one of which is the RAS 
pathway. It is interesting to note that TEL contains 
three candidate MAPK sites (Clark-Lewis et a l , 1991; 
Gonzalez et a l , 1991) at amino acid positions 20-23, 
200-204 and 255-258 indicating that activity of the 
protein may be regulated by MAPK, via the RAS 
pathway. In this respect it is interesting that a number 
of t(12;22) patients, including p2 , presents with a 
CML-like disease (Mitelman, 1991) while in CML 
tumorigenicity of the BCR-ABL protein in part 
depends upon continuous activation of the RAS 
signaling pathway (Pendergast et a l , 1993). In much 
the same way, the supposedly activated tyrosine kinase 
of the TEL-PDGFR/? protein in CMML would result 
in activation of the RAS pathway. This indicates that 
RAS activation (Sawyers and Denny, 1994) and 
thereby probably activation of members of the ETS 
family of transcription factors plays a central role in 
the genesis of myeloid leukemia. Also the description 
of an altered ERG gene in AML carrying a t(16;21) 
(Shimizu et a l , 1993) could conform to this general
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picture. Although TEL mRNA is ubiquitously 
expressed, it remains to be analysed whether the 
protein is a natural target of the RAS pathway. 
Alternatively, if TEL is not a downstream target of 
RAS, the activated MN1-TEL protein may feed into 
the same downstream processes by competition for 
DNA binding sites that would normally be occupied by 
RAS-responsive ETS proteins, activating genes essen­
tial for myeloid transformation.
To date, we have isolated 155 kb of genomic TEL  
sequences. Since the map of the large intron is 
incomplete and genomic DNA encoding the 5' and 3' 
UTRs still needs to be isolated, the gene may extend 
much farther. The involvement of TEL  in t(5;12) 
(Golub et a l , 1994) and t(12;22), in combination with 
detection of 12pl2-13 aberrations in 0 .5 -2%  of 
myeloid (Adriaansen, 1992) and 1 0 % of pediatric 
lymphoid (Raimondi et a l , 1986) malignancies make 
this gene a prime candidate for other chromosomal 
translocations or deletions involving this region. This 
possibility is currently under investigation. In contrast 
to most cases with chromosome 12p 12-13 abberations 
(Mitelman, 1991), t(12;22) is often the sole karyotypic 
abnormality* despite the variable phenotype of the 
leukemia. We favor the idea that additional, unde­
tected mutations lead to diversification, while activa­
tion of TEL is only one of the necessary steps in 
malignant transformation. In this respect it is 
worthwhile to mention that p2 and p3 showed the 
translocation at relapse after treatment with cytostatic 
agents.
The most remarkable feature of TEL in these 
translocations seems that separate domains of the 
protein contribute to distinct fusion proteins that, 
although different in function, could lead to deregula­
tion of the same downstream targets needed for 
transformation of myeloid progenitors.
Southern blotting
D N A  o f relevant hybrid cell lines was digested with various 
enzymes and electrophoresed on a 0.7% agarose gel. D N A  
was blotted onto nylon membranes (Hybond N +, Amer- 
sham, UK ). Filters were hybridized according to standard 
procedures (Sambrook et a l , 1989) with probes labeled by 
random priming (Feinberg and Vogelstein, 1983). Filters 
were washed at a stringency o f 0.3 x  SSC at 65°C.
Construction o f  genomic XEMBL3 library
A genomic AEMBL3 library was constructed o f 300 fig 
D N A  o f bone marrow from p 2 according to Frischauf et 
a l  (1983). Recombinant phages (106) were plated and 
screened with a 4.4 kb E co R l  genomic fragment (pUK 4) o f  
M N 1. Phages that showed a restriction pattern diverging 
from wild-type M N 1  phages were considered as putative 
breakpoint containing recombinants and were analysed for 
chromosomal localization by FISH (Hagemeijer et a l ,
1993). A  genomic map o f chromosome the 12pl3 region 
was generated by chromosome walking. Before hybridiza­
tion, probes were competed with 1 0 0  fig o f  human 
competitor D N A  (Sigma, St. Louis, MO) for 1.5 h in 
100 fû 5 x SSC at 65°C.
Fluorescent in situ hybridization
FISH was done according to Hagemeijer et a l  (1993). 
Chromosomes were identified by 4', 6/-diamino-2-phenyl 
indole (DAPI) banding, using a fluorescence microscope 
equipped with FITC .and DAPI filters.
RN A isolation
Total RN A  was isolated from bone marrow o f patients or 
from A3JA hybrid cell lines using the acidic guanidinium  
thiocyanate method (Chomczynski and Sacchi, 1987). 
Poly(A) + R N A  was isolated using the PolyA Tract m R N A  
Isolation System III (Promega, M adison, WI).
Materials and methods
Patients and cell lines
Patient 1 (p i), a 19-year-old woman was diagnosed with 
AML-M4. Cytogenetic analysis on bone marrow showed a 
karyotype 47,XX, + 8 , t(12;22)(pl3;ql 1 ). Patient 2  (p2 ), a 
58-year-old man, was diagnosed with (Ph chromosome 
negative) CML. Cytogenetic analysis o f  bone marrow 
showed a normal karyotype. Treatment with hydroxyurea 
was started and clinical status improved. However, 2 years 
later the patient relapsed with accelerated disease. 
Cytogenetic analysis of blood and bone marrow revealed 
a karyotype 46,XY, t(12;22)(pl3;ql2). Clinical and 
cytogenetic status has recently been described in detail 
(Geurts van Kessel et a l , 1994). Patient 3 (p3), a 15-year- 
old boy, was diagnosed with myelodysplastic Syndrome 
(RAEB). At diagnosis the karyogram was normal. 
Antileukemic treatment was started. One year later 
cytogenetic analysis revealed a karyogram 46, XY, 
t(12;22)(pl3;ql 1).
A hamster/human hybrid cell line panel was generated by 
fusion o f hamster fibroblast cell line A3 with bone marrow 
cells of p i using inactivated Sendaivirus (Geurts van Kessel et 
al., 1981). Hybrid cell lines were cultured in Ham’s F10 
medium+10%  FCS supplemented with lx H A T . Cytoge­
netic analysis of patient material and hybrid cell lines was 
done according to standard methods (Hagemeijer et a l , 
1979).
R A C E  cloning
Poly (A )+ R N A  ( 1  fig) o f  p2  was used to clone 5' T E L - 3 '  
MN1 fusion cD N A  using the 5;-A m pliFIN D ER ™  RACE  
Kit (Clontech Laboratories, Palo Alto, CA). First strand 
cD N A  was synthesized with MN1 antisense primer 1 (5'-
AGTTAGGGCAGCCACGAATG-3'). A nested antisense 
MN1 primer 2 (5'- CTT G A ATTCCC A A AT CT GTT G- 
GAG-3') was used in the PCR reaction. PCR was 
performed using three cycles o f denaturation (45 s, 94°C), 
annealing (45 s, 45°C) and extension ( 2  min, 72°C, 
followed by 32 cycles o f denaturation (45 s, 94°C), 
annealing (45 s, 62°C) and extension (2 min, 72°C). PCR  
products were visualized by electrophoresis on a 2 % 
agarose gel. PCR products were phenol/chloroform  
extracted, precipitated and digested with E coR l.  After 
digestion the products were subcloned in pBluescript KS~ 
(Stratagene, La Jolla, CA) and sequenced using USB  
Sequenase™ Version 2.0 D N A  sequencing Kit (USB, 
Cleveland, OH).
cDNA cloning
A human placenta cD N A  library in A gtll (106 pfu) 
(Clontech Laboratories, Palo Alto, CA) was screened 
using a 5' TEL-specific 246 bp E c o R l - X h o l  cD N A  
fragment o f p2, resulting in the isolation o f a 1.7 kb TEL  
cD N A  clone hpc7A.
R T -P C R
M N1-TEL and TEL-MN1 junctions were amplified using 
two sets o f primers. 5 ng  total R N A  or 1 fig poly(A) + 
R N A  was used to synthesize first strand cD N A  with MN1 
antisense primer 1 with AM V Reverse Transcriptase 
(Promega, Madison, WI) at 42°C. PCR was performed 
using one cycle of dénaturation (5 min, 94°C), annealing 
(5 min, 59°C) and extension (5 min, 72°C), followed by 24 
cycles o f dénaturation (2 min, 94°C), annealing (2 min, 
59°C) and extension (3 min, 72°C) with TEL sense primer 6
(5'-AGTGTAGCATTAAGCAGGAACG-3'). 2.5 ¡i\ of
PCR reaction was used in a second round of PCR with 
TEL primer 6 and MN1 primer 2  (Figure 4b), using three 
cycles o f dénaturation (2 min, 94°C), annealing (2 min, 
47°C) and extension (3 min, 72°C) followed by 30 cycles o f  
dénaturation (2 min, 94°C), annealing (2 min, 60°C) and 
extension (3 min, 72°C). In case of MN1-TEL junction 
cD N A  fragments TEL antisense primer 4 (5'-GTAT- 
GACCTCCGGCTG-3') was used to synthesize first strand 
cD N A . PCR was performed using M N 1 sense primer 3 (5'- 
TCCAGCTACAGAGGCA-3') for one cycle of dénatura­
tion (5 min, 94°C), annealing (5 min, 47°C), and extension 
(5 min, 72°C) followed by 24 cycles o f dénaturation (2 min, 
94°C), annealing ( 2  min, 47°C) and extension (3 min, 
72°C). 2.5 fi 1 o f this PCR reaction was used in a second 
amplification with nested antisense TEL primer 5, (5'-
CCAGGGTGGAAGAATG-3'), for 30 cycles of denatura-
tion (2 min, 94°C), annealing (2 min, 47°C) and extension 
(3 min, 72°C). 10 n 1 o f the PCR reaction was electrophor- 
esed on a 2 % agarose gel and blotted onto nylon 
membranes (Hybond N +, Amersham, UK). Membranes 
were hybridized using either MN1 cDNA 2.2 probe and a 
246 bp E c o R l - X h o l  TEL-specific 5' cD N A  fragment. PCR 
products were subcloned and sequenced.
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